Buying guide
Garmin (Venu / Fenix / Forerunner) vs Stelo in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
- Garmin (Venu / Fenix / Forerunner) has more capabilities independently verified as autonomous (2 vs 0).
- Stelo has the lower recorded price.
| Attribute | ||
|---|---|---|
| Manufacturer | Garmin | Dexcom |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Autonomy | ✓ 2 verified autonomous | — |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $449-$1,699 (actual sale price) | $89-$99 (actual sale price) |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 1Global | 1Global |
| Privacy practices | 5location-tracking, third-party-sharing, data-retention, data-deletion-control, cloud-upload | 4biometric-storage, training-data-use, third-party-sharing, data-deletion-control |
| Sources on file | 19 | 11 |
Editorial summaries
Garmin (Venu / Fenix / Forerunner)
Garmin (the Venu 3 as the biometric-primary anchor at about $449; the Fenix 8 and Forerunner 965 are more athletics-primary and pricier) is the lightest-cleared-portfolio entry in the biometric cohort. Its sensors (Elevate optical heart rate, Pulse Ox/SpO2, ECG on select models, skin temperature) drive Body Battery, Training Load and Training Readiness, advanced sleep and a sleep coach, all-day stress and HRV Status, and a Morning Report. The verified-vs-claimed distinction matters here: only the ECG is FDA-cleared (a 510(k) in 2023, on select models); Body Battery, recovery, and the broader readiness metrics are wellness-grade, and Pulse Ox is not FDA-cleared. Garmin is purchase-only (founded 1989); the optional Garmin Connect+ AI subscription ($6.99/month, March 2025) does not gate any existing features. DEPLOY cap-flags any reading of Garmin's wellness metrics as cleared diagnostics; only the ECG carries a clearance.
Stelo
Dexcom's Stelo is the first-ever FDA-cleared over-the-counter (no-prescription) glucose biosensor (De Novo, March 5, 2024; US launch August 26, 2024): a 15-day continuous glucose monitor for adults 18+ not on insulin (type 2 not on insulin, plus non-diabetic users tracking how diet and exercise affect glucose). It is the generative-AI end of the glucose cell: Weekly Insights run on Google Cloud's Vertex AI and Gemini, with AI photo meal-logging and personalized daily recommendations, the AI substance that carries it across the biometric boundary. Pricing is about $89 for a 2-week sensor on a biweekly subscription model (around $99/month). From DexCom (NASDAQ: DXCM), Stelo is the OTC product line, separate from the prescription G7. Cap-flag: the cleared indication is an OTC CGM for adults 18+ not on insulin; it is explicitly NOT cleared for problematic hypoglycemia and has no low-glucose alerts, so it should not be read as a diabetes-management device.
Common questions
- What is the difference between Garmin (Venu / Fenix / Forerunner) and Stelo?
- Garmin (Venu / Fenix / Forerunner) and Stelo are both biometric robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
- Which is cheaper, Garmin (Venu / Fenix / Forerunner) or Stelo?
- Stelo has the lower recorded price on the DEPLOY registry than Garmin (Venu / Fenix / Forerunner). Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.
- Is Garmin (Venu / Fenix / Forerunner) or Stelo more autonomous?
- Garmin (Venu / Fenix / Forerunner) has more capabilities independently verified as autonomous on the DEPLOY registry than Stelo. DEPLOY counts a capability as autonomous only when verified at a real deployment, not from a demo or a vendor claim.
- Which has more verified deployments, Garmin (Venu / Fenix / Forerunner) or Stelo?
- Garmin (Venu / Fenix / Forerunner) and Stelo each have 1 verified deployment on the DEPLOY registry (confirmed at named sites with primary sources).
Recent coverage
- Dexcom’s latest executive pay disclosure covers new CEO’s big yearStelo · Medical Design & Outsourcing · 2026-06-15
- Will Giving Everyone a Blood Sugar Monitor Lead to Better Health Outcomes? Maybe, But Only If We Tell People What to Do With The InfoStelo · The Spoon · 2026-01-15
Related comparisons
- Lingo vs Garmin (Venu / Fenix / Forerunner)
- Apple Watch vs Garmin (Venu / Fenix / Forerunner)
- Fitbit (Charge / Sense / Versa) vs Garmin (Venu / Fenix / Forerunner)
- Garmin (Venu / Fenix / Forerunner) vs Evie Ring (and EvieMED)
- Garmin (Venu / Fenix / Forerunner) vs Oura Ring 4
- Garmin (Venu / Fenix / Forerunner) vs Pixel Watch
- Garmin (Venu / Fenix / Forerunner) vs RingConn (Gen 2 / Gen 3)
- Garmin (Venu / Fenix / Forerunner) vs Samsung Galaxy Ring
- Garmin (Venu / Fenix / Forerunner) vs Samsung Galaxy Watch (and Galaxy Ring)
- Garmin (Venu / Fenix / Forerunner) vs Ultrahuman Ring (Air / Pro)
- Garmin (Venu / Fenix / Forerunner) vs Whoop (5.0 / MG)
- Garmin (Venu / Fenix / Forerunner) vs Withings ScanWatch
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

